Despite the growing crisis of antibiotic resistance, large pharma companies have been exiting the arena for years, including Allergan, Sanofi and Novartis in 2018 alone. Genentech, a member of the Roche Group, is one of the few remaining large companies that continues to invest in the discovery and development of new antimicrobials. Rick Brown, who has worked at Genentech for 12 years and is vice president of Immunology and Infectious Diseases, spoke with Katie Kingwell about the challenges of discovering novel antibiotics and how Genentech approaches this daunting but important task.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Rick Brown. Nat Rev Drug Discov 18, 10–11 (2019). https://doi.org/10.1038/nrd.2018.237
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.237
